Hemady is a drug owned by Dexcel Pharma Technologies Ltd. It is protected by 2 US drug patents filed from 2020 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 18, 2037. Details of Hemady's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10537585 | Compositions comprising dexamethasone |
Dec, 2037
(12 years from now) | Active |
| US11304961 | Compositions comprising dexamethasone |
Dec, 2037
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Hemady's patents.
Latest Legal Activities on Hemady's Patents
Given below is the list of recent legal activities going on the following patents of Hemady.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2023 | US10537585 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Apr, 2022 | US11304961 |
| Recordation of Patent Grant Mailed Critical | 19 Apr, 2022 | US11304961 |
| Email Notification Critical | 31 Mar, 2022 | US11304961 |
| Issue Notification Mailed Critical | 30 Mar, 2022 | US11304961 |
| Application Is Considered Ready for Issue Critical | 28 Mar, 2022 | US11304961 |
| Dispatch to FDC | 28 Mar, 2022 | US11304961 |
| Issue Fee Payment Verified Critical | 07 Mar, 2022 | US11304961 |
| Issue Fee Payment Received Critical | 07 Mar, 2022 | US11304961 |
| Mail Notice of Allowance Critical | 02 Mar, 2022 | US11304961 |
FDA has granted several exclusivities to Hemady. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Hemady, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Hemady.
Exclusivity Information
Hemady holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Hemady's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
US patents provide insights into the exclusivity only within the United States, but Hemady is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Hemady's family patents as well as insights into ongoing legal events on those patents.
Hemady's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Hemady's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 18, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Hemady Generic API suppliers:
Dexamethasone is the generic name for the brand Hemady. 30 different companies have already filed for the generic of Hemady, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Hemady's generic
Alternative Brands for Hemady
Hemady which is used for treating adults with multiple myeloma., has several other brand drugs using the same active ingredient (Dexamethasone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Eyepoint Pharms |
| |
| Harrow Eye |
| |
| Ocular Therapeutix |
| |
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dexamethasone, Hemady's active ingredient. Check the complete list of approved generic manufacturers for Hemady
About Hemady
Hemady is a drug owned by Dexcel Pharma Technologies Ltd. It is used for treating adults with multiple myeloma. Hemady uses Dexamethasone as an active ingredient. Hemady was launched by Dexcel in 2019.
Approval Date:
Hemady was approved by FDA for market use on 03 October, 2019.
Active Ingredient:
Hemady uses Dexamethasone as the active ingredient. Check out other Drugs and Companies using Dexamethasone ingredient
Treatment:
Hemady is used for treating adults with multiple myeloma.
Dosage:
Hemady is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG | TABLET | Prescription | ORAL |